AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through fiscal 2025, year ended Dec 31, 2025
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
Ownership
Who owns Astrazeneca's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
1 buys · 1 sales
Net sold $2.21M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vanguard Capital Management | 77,965,099 | 5.02% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 117,761,076 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mani Sharma | See Remarks | 19,289 | 0.00% | Sep 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mani Sharma See Remarks | Sep 8, 2026 | Award | +1 | $162.60 | $163 | 19,289 |
| Mani Sharma See Remarks | Aug 8, 2026 | Buy | +20.23 | $160.57 | $3.25K | 19,288 |
| Mani Sharma SVP, Group Controller | Aug 6, 2026 | Award | +2 | $163.34 | $327 | 19,267 |
| Mani Sharma See Remarks | Jul 6, 2026 | Award | +2 | $190.43 | $381 | 19,265 |
| Mani Sharma See Remarks | Jun 8, 2026 | Award | +1 | $179.75 | $180 | 19,263 |
| Mani Sharma See Remarks | May 20, 2026 | Sale | −11,893 | $185.78 | $2.21M | 19,262 |
| Mani Sharma See Remarks | May 6, 2026 | Award | +1 | $186.28 | $186 | 31,155 |
| Mani Sharma See Remarks | Apr 7, 2026 | Award | +1 | $196.03 | $196 | 31,154 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sarin Aradhana Officer | Nov 12, 2025 | 15,000 | $1.33M | Nov 12, 2025 | Restricted stock vesting under a registered plan |
| Sarin Aradhana Officer | Nov 13, 2023 | 52,181 | $3.62M | Nov 22, 2022 | 50,806 securities to be sold were obtained at completion of the merger between Alexion Pharmaceuticals, Inc and AstraZeneca PLC under the related Form F-4 registration statement |